{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:03:03Z","timestamp":1762444983834},"reference-count":15,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Topical imiquimod is commonly used in the nonsurgical management of actinic keratosis and superficial basal cell carcinoma. Although adverse effects have been limited primarily to local irritation, another rare adverse reaction is erythema multiforme. We present a case of erythema multiforme involving the oral mucosa, trunk, and extremities that followed broad application of topical imiquimod for the management of suspected superficial basal cell skin cancers and actinic keratosis. The patient had used imiquimod previously without complication. Cessation of use and systemic corticosteroids resulted in prompt clearance.<\/jats:p>","DOI":"10.7556\/jaoa.2020.010","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T14:30:46Z","timestamp":1576506646000},"page":"45-48","source":"Crossref","is-referenced-by-count":5,"title":["Topical Imiquimod and Subsequent Erythema Multiforme"],"prefix":"10.1515","volume":"120","author":[{"given":"Luke","family":"Maxfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gaston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Peck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"key":"2021032621215475533_j_jaoa.2020.010_ref_001_w2aab3b7b9b1b6b1ab2ab1Aa"},{"issue":"4","key":"2021032621215475533_j_jaoa.2020.010_ref_002_w2aab3b7b9b1b6b1ab2ab2Aa","first-page":"467","article-title":"Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of 2 phase-3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","year":"2005","journal-title":"Arch Dermatol"},{"key":"2021032621215475533_j_jaoa.2020.010_ref_003_w2aab3b7b9b1b6b1ab2ab3Aa","first-page":"476","volume-title":"Topical and intralesional antiviral agents. In: Wolverton S, ed. Comprehensive Dermatologic Drug Therapy","year":"2013","edition":"3rd ed"},{"issue":"2","key":"2021032621215475533_j_jaoa.2020.010_ref_004_w2aab3b7b9b1b6b1ab2ab4Aa","article-title":"Erythema multiforme as a reaction to imiquimod 5% cream","volume":"23","year":"2017","journal-title":"Dermatol Online J"},{"issue":"7","key":"2021032621215475533_j_jaoa.2020.010_ref_005_w2aab3b7b9b1b6b1ab2ab5Aa","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1111\/ijd.12265","article-title":"Erythema multiforme induced by imiquimod 5% cream","volume":"53","year":"2014","journal-title":"Int J Dermatol"},{"issue":"3","key":"2021032621215475533_j_jaoa.2020.010_ref_006_w2aab3b7b9b1b6b1ab2ab6Aa","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ad.2017.08.007","article-title":"Erythema multiforme caused by treatment with topical imiquimod 5% in a patient with Gorlin syndrome","volume":"109","year":"2018","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"2021032621215475533_j_jaoa.2020.010_ref_007_w2aab3b7b9b1b6b1ab2ab7Aa","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ad.2009.12.023","article-title":"Erythema multiforme due to 5% imiquimod cream [in Spanish]","volume":"101","year":"2010","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"2021032621215475533_j_jaoa.2020.010_ref_008_w2aab3b7b9b1b6b1ab2ab8Aa","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1111\/ajd.12578","article-title":"Erythema multiforme triggered by imiquimod 5% cream","volume":"58","year":"2017","journal-title":"Australas J Dermatol"},{"issue":"432","key":"2021032621215475533_j_jaoa.2020.010_ref_009_w2aab3b7b9b1b6b1ab2ab9Aa","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2011-050025","article-title":"Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation","volume":"87","year":"2011","journal-title":"Sex Transm Infect"},{"issue":"5","key":"2021032621215475533_j_jaoa.2020.010_ref_010_w2aab3b7b9b1b6b1ab2ac10Aa","doi-asserted-by":"publisher","first-page":"AB223","DOI":"10.1016\/j.jaad.2016.02.877","article-title":"Topical imiquimod\u2014be aware of the unexpected","volume":"74","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2021032621215475533_j_jaoa.2020.010_ref_011_w2aab3b7b9b1b6b1ab2ac11Aa","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1046\/j.1523-1747.1999.00754.x","article-title":"Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions","volume":"113","year":"1999","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2021032621215475533_j_jaoa.2020.010_ref_012_w2aab3b7b9b1b6b1ab2ac12Aa","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12016-017-8667-7","article-title":"Current perspectives on erythema multiforme","volume":"54","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"2021032621215475533_j_jaoa.2020.010_ref_013_w2aab3b7b9b1b6b1ab2ac13Aa","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","article-title":"CD4 T cells: fates, functions, and faults","volume":"112","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2021032621215475533_j_jaoa.2020.010_ref_014_w2aab3b7b9b1b6b1ab2ac14Aa","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.4049\/jimmunol.1403015","article-title":"Dual inhibition of TNFR1 and IFNAR1 in imiquimod-induced psoriasiform skin inflammation in mice","volume":"194","year":"2015","journal-title":"J Immunol"},{"issue":"3","key":"2021032621215475533_j_jaoa.2020.010_ref_015_w2aab3b7b9b1b6b1ab2ac15Aa","first-page":"51","article-title":"The role of systemic corticosteroid therapy in erythema multiforme major and Stevens-Johnson syndrome: a review of past and current opinions","volume":"2","year":"2009","journal-title":"J Clin Aesthet Dermatol"}],"container-title":["Journal of Osteopathic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2020.010\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2020.010\/html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T21:22:33Z","timestamp":1616793753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2020.010\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,1]]},"published-print":{"date-parts":[[2020,1,1]]}},"alternative-id":["10.7556\/jaoa.2020.010"],"URL":"https:\/\/doi.org\/10.7556\/jaoa.2020.010","relation":{},"ISSN":["2702-3648"],"issn-type":[{"value":"2702-3648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,16]]}}}